Abstract. Human telomerase reverse transcriptase (hTerT) promoter has been proposed in cancer-targeted gene therapy. However, this promoter has not been strong enough to achieve therapeutic levels of transgene expression. We favor the hypothesis that telomerase may participate in the process of dna repair and that the up-regulation of hTerT promoter activity may be a reaction to dna damage. in previous investigations, we tested an ῾indirected-activator' strategy that utilizes radiation to increase the activity of the hTerT promoter. The purpose of the present study was to implement a strategy using cisplatin to enhance hTerT promoter activity. The results indicate that, in human uterine cervical cancer (HeLa) cells exposed to 5 µg/ml cisplatin, the hTerT promoter had 3.1-fold increased activity compared to untreated cells. in addition, the combination of cisplatin and hTerT promoter-mediated horseradish peroxidase/indole-3 -acetic acid gene-directed enzyme prodrug therapy induced cell cycle arrest at the S phase and apoptosis leading to a more significant reduction in cell viability. These findings suggest that hTerT promoter-mediated gene therapy is improved when combined with cisplatin.
Introduction
Selective gene therapy, which utilizes a tumor-specific promoter to control the transgene, represents a potent strategy in cancer treatment. Telomerase is a ribonucleoprotein complex that is activated in approximately 90% of cancers, but not in most normal cells (1) . Human telomerase reverse transcriptase (hTerT) is the catalytic subunit of telomerase, and determines telomerase activity (2) . Thus, the hTerT promoter has been widely used in gene therapy targeting cancer cells (3, 4) . However, the activity of the promoter may not be strong enough to induce the expression of a significant amount of the therapeutic gene product required to kill cancer cells (5, 6) .
radiotherapy is one of the major clinical treatment options for malignant tumors; however, cellular dna damage responses are triggered when cells are exposed to irradiation. data from our previous investigations suggested that telomerase plays a role in healing radiation-induced dna damage (7) . We also observed that radiation can be used to increase the activity of the hTERT promoter (8) . Cisplatin is one of the most efficient chemotherapeutic agents in use, exerting its cytotoxic effect through the formation of intra-strand and inter-strand Pt-dna cross-links. We favor the hypothesis that telomerase may participate in the process of dna repair, and that the up-regulation of hTerT promoter activity may be a reaction to dna damage. Thus, cisplatin may be used to enhance hTerT promoter activity. This is promising in cancer-targeted gene therapy.
The aim of the present study was to determine the potential of utilizing cisplatin to enhance hTerT promoter activity. The human uterine cervical cancer cell line Hela was used, since the hTerT promoter has been applied to mediate tumorspecific expression in cervical cancer cells (9, 10) . Cisplatin is the standard systemic chemotherapeutic agent for cervical cancer (11) . The relationship between dosage of cisplatin and the induced activity of the hTerT promoter was examined. in addition, the horseradish peroxidase (HrP)/indole-3-acetic acid (iaa) gene-directed enzyme prodrug therapy (gdePT) system was used to determine whether the combination of cisplatin and hTerT promoter-controlled gene therapy was effective as a cancer gene therapy. Proliferation rate and the apoptosis index were used to evaluate this strategy. changes in cell cycle distribution were also investigated.
Materials and methods
Cell culture. The human uterine cervical cancer cell line Hela (aTcc, ccl-2) was obtained from the china center for Type culture collection. cells were cultured in rPMi-1640 medium supplemented with 10% calf serum (gibco, uSa) and maintained at 37˚C in 5% CO 2 in a humidified incubator.
Plasmid DNA and cell transfection. The core hTerT promoter (-385/+40 bp) was kindly provided by dr i. Horikawa (niH/ nci, uSa) (12) and was cloned into the pgl3-Basic vector (Promega, uSa) to generate phTerTp-luc. For plasmid phTerTp, in which the hTerT promoter (hTerTp) does not control the expression of any gene, hTerTp replaced the cMv promoter in pcdna3.1(-) (invitrogen, uSa). Plasmid prk5-HrP was a kind gift from dr d.F. cutler (ucl, uk) (13) . For phTerTp-HrP, the HrP cdna was cloned into the phTerTp plasmid, driven by hTerTp. cells were transfected using the Metafectene method (Biontex laboratories gmbH, germany) according to the manufacturer's instructions.
Reporter gene assay. Plates (24-well) were seeded with 1x10 5 cells/well. At an optical confluency of 90-100%, cells were cotransfected with 0.25 µg of plasmid phTERTp-Luc or pGL3-Basic (negative control plasmid; Promega) and 0.25 µg of prl-Tk (cotransfected standard plasmid; Promega) (Metafectene 2 µl) per well. Cells were exposed to 0, 1, 2 or 5 µg/ml cisplatin after transfection for 24 h and lysed for luciferase activity analysis using the dual-luciferase reporter assay system (Promega) as indicated by the manufacturer. Internal normalization of transfection efficacy was performed using the value of renilla luciferase (rl). The value of luciferase activity in negative control cells (cotransfected pgl3-Basic and pRL-TK) reflected the background, and was deducted.
Cell viability by MTT assay. The sensitivity of Hela cells towards cisplatin was determined by the MTT assay as described previously (14) . in brief, 3x10 4 cells/well were seeded in a 96-well plate. after 24 h, the cells were transfected with plasmid phTERTp-HRP (DNA, Metafectene 0.1 µg:0.6 µl). after transfection for 24 h, cisplatin at concentrations of 0, 1, 2 and 5 µg/ml was diluted with 200 µl of medium and added to each well (6 parallel samples in each group). The cells were exposed to the drug for an additional 44 h, then incubated for 4 h with 20 µl of methylthiazolyltetrazolium (MTT; Sigma, USA) at a concentration of 5 g/l at 37˚C in a 5% CO 2 atmosphere. Subsequently, 150 µl dimethyl sulphoxide was added to each well, and the cells were agitated for 10 min. cisplatin-treated cell viability was expressed as the percentage of cell proliferation of the control cells [(a492 treated cells/a492 control cells) x 100] after correction for background absorbance.
Analysis of apoptosis by flow cytometry. Hela cells were washed twice with rPMi-1640 medium. adherent cells were detached using 0.25% trypsin in 0.02% edTa and pelleted by centrifugation at 800 rpm for 5 min. The cells (1x10 5 ) were washed twice in PBS at 4˚C and resuspended in 100 µl of binding buffer containing Annexin V/FITC (5 µl) and propidium iodide (PI) (10 µl, 20 µg/ml) for 15 min in the dark. With the addition of 0.4 ml PBS, stained cells were analyzed for apoptosis by collecting 10,000 counts using the cytomics™ Fc500 Flow cytometer (Beckman coulter, uSa).
Cell cycle analysis by flow cytometry. cell cycle phases (g0/ g1, S or g2/M) were characterized according to dna content. The fluorescent dye PI binds with DNA strongly at a ratio of 1:1; hence, the dna contents of the cell cycle phases were reflected by varying PI fluorescence intensities. HeLa cells were washed twice with rPMi-1640 medium, and adherent cells were detached using 0.25% trypsin in 0.02% edTa and pelleted by centrifugation at 800 rpm for 5 min. The cells (1x10 5 ) were washed twice in PBS at 4˚C and fixed in 70% ice-cold (4˚C) ethanol. Cell pellets were resuspended in 1 mg/ ml RNase solution (Sigma, USA) for 30 min at 37˚C, and then in 0.1 mg/ml PI solution (Sigma) for 30 min at 4˚C in the dark. cell cycle analysis was performed on the cytomics™ Fc500 flow cytometer.
Statistical analysis. results are expressed as the mean ± Sd. differences between groups were analyzed by the one-way anova test. data were analyzed using SPSS13.0 software (SPSS inc., uSa). The differences were considered statistically significant at P<0.05.
Results

Effect of cisplatin on the activity of the hTERT promoter in
HeLa cells. in order to establish whether exogenous hTerT promoter activity was modulated by cisplatin, firefly luciferase was used as the reporter gene to determine the instantaneous activation of the hTerT promoter after cisplatin exposure. rl was used for internal normalization, and pgl3-Basic was used as a negative control and background value. Transfected Hela cells were treated for 24 h with increasing concentrations of cisplatin, ranging from 0 to 5 µg/l. As shown in Fig. 1 , induced activity of the hTerT promoter was expressed in a dose-dependent manner. The peak of hTerT promoter activity (3.11±1.03-fold increase) was detected in cells treated with 5 µg/ ml cisplatin (Fig. 1) . in order to verify the induction of hTerT promoter by cisplatin, 5 µg/ml of cisplatin was adopted for the following experiments.
Effect of cisplatin on HeLa cell proliferation. The cytotoxicity of cisplatin to Hela cervical cancer cells was investigated after an incubation period of 48 h using the colorimetric MTT assay. as shown in Fig. 2 , Hela cell proliferation was inhibited in a dose-dependent manner in response to increasing concentrations of cisplatin (0-5 µg/ml). Inhibition of 49.61±8.94% was Figure 1 . effect of cisplatin (ddP) on exogenous hTerT promoter activity in Hela cells. hTerT promoter activity after exposure to cisplatin in Hela cells was evaluated by luciferase activity assay. cells were treated with increasing concentrations of cisplatin and collected 24 h after exposure. exogenous hTerT promoter activity was expressed as the fold induction relative to that of cells that received 0 µg/ml cisplatin treatment. Data are expressed as the means ± Sd of three experiments performed in triplicate.
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obtained with a cisplatin concentration of 5 µg/ml. In contrast, no obvious cytotoxicity to Hela cells was observed after incubation with 1 µg/ml of cisplatin, as verified by the MTT assay (Fig. 2) .
Effect of combining phTERTp-HRP/IAA with cisplatin on cell viability. The efficacy of hTERT promoter induction was investigated after the HeLa cells were exposed to 5 µg/ml of cisplatin (Fig. 1) . We hypothesized that cisplatin could be used to improve the efficiency of hTERT promoter-mediated gene therapy. To evaluate the application of this strategy, phTerTp-HrP plasmids were transiently transfected into Hela cells. Twenty four hours after transfection, the cells were divided into four groups according to treatment: a) HrP (PBS); b) HRP+cisplatin (DDP) (5 µg/ml DDP); c) HRP+IAA (0.5 mmol/l IAA); and d) HRP+DDP+IAA (5 µg/ml DDP and 0.5 mmol/l iaa).
The cytotoxic effects of combining phTerTp-HrP/iaa with cisplatin on Hela cells were measured following treatment using the MTT assay (Fig. 3) . inhibition of 25.34±3.40% was obtained in transfected Hela cells after incubation with 0.5 mM iaa, while 47.80±3.46% of the cells survived exposure to 5 µg/ml cisplatin. Conversely, when HRP/IAA controlled by the hTerT promoter was combined with cisplatin, only 11.05±3.67% of the Hela cells survived iaa incubation, indicating the synergistic effect of this combination strategy.
Effect of combining phTERTp-HRP/IAA with cisplatin on cell apoptosis and the cell cycle. The significant growth inhibitory activity of combining phTerTp-HrP/iaa with cisplatin led us to investigate whether part of this effect was the result of changes in programmed cell death induction and the cell cycle.
as shown in Fig. 4 , apoptosis analysis indicated that Hela cells treated with a combination of phTerTp-HrP/iaa and cisplatin underwent marked apoptosis with an early apoptotic rate of 39.82±2.61%, 14.2-fold higher than that of the control cells. a 4.1-fold increase in the apoptosis of cells treated with cisplatin alone and a 5.0-fold increase in those treated with iaa alone was estimated and compared to the control cells, as assessed by the early apoptotic rate.
cell cycle analysis revealed that the combination treatment provoked an inhibition of S phase cell cycle progression (Table i ). The combination of phTerTp-HrP/iaa and cisplatin induced an increase in the number of cells in the S phase (15) . in developing countries, cervical cancer is the second leading cause of cancer mortality in women (15) . effective cytotoxic treatment options for advanced cervical cancer are exceedingly limited (16) , and the survival rate of patients with cervical cancer has not improved substantially over the past 25 years (17) . cisplatin is regarded as the most active agent in carcinoma of the cervix, and cisplatin-based combination chemotherapy is most commonly applied, resulting in response rates of 7-78% and overall survival of less than 25 months (11). new treatment strategies are therefore necessary. cancer gene therapy is an interesting approach for cervical cancer patients, as the specific delivery of DNA vector to cancer cells by local injection is feasible. one limitation of cancer gene therapy is its toxicity to normal cells. Targeted gene therapy exploits differences between malignant and normal tissue cells in order to preferentially express therapeutic genes in tumor cells. Telomerase is a ribonucleoprotein complex activated in approximately 90% of cancers, but not in most normal cells (1) . Human telomerase consists of a catalytic protein subunit (hTerT) and a rna subunit (hTr). The transcriptional regulation of hTerT largely controls telomerase activity (2) . hTerT promoter with activation only in cells with active telomerase has been widely used in gene therapy for targeting cancer cells (3, 4) . However, hTerT promoter may not be strong enough to achieve therapeutic levels of transgene expression (5, 6) .
Telomerase activation is a relatively early-stage event in cervical carcinogenesis (18) , and it may be possible to use the hTerT promoter to restrict transgene expression to cervical cancer cells. on this basis, researchers have developed novel strategies mediated by the hTerT gene promoter to achieve tumor-selective killing ability for cervical cancer (9,10). However, to maximize the therapeutic efficiency of this strategy, it is necessary to enhance the activity of the hTerT promoter. We previously demonstrated that telomerase participates in the process of dna repair, and that the upregulation of telomerase activity may be a reaction to dna damage induced by irradiation (7) . Thus, the hTerT promoter may be indirectly enhanced in response to dna-damaging agents. in our previous studies, we found that the activities of exogenous and endogenous hTerT promoter in Hep-2 cells can be induced by irradiation. This ῾indirected-activator' strategy may be capable of amplifying the targeted killing effect of hTerT promoter-mediated gene therapy in vitro and in vivo (8, 19) .
cisplatin is one of the most widely-used dna-damaging agents in the treatment of cancer. in this study, cisplatin not only killed tumor cells by damaging dna, but also up-regulated the activity of the hTerT promoter. using a dual-luciferase reporter assay, we observed that the hTerT promoter was maximally enhanced by 5 µg/ml cisplatin compared to other doses. However, the published data on the relationship between the effects of cisplatin and changes in telomerase activity are conflicting (20) . In this study, low-dose (0-2 µg/ml) cisplatin exposure resulted in little enhancement of hTerT promoter activity. This may be due to the minimal dna damage it effected. in contrast, high dose cisplatin treatment resulted in marked cancer cell killing, and telomerase activity was decreased in dying cells (21) . Since the precise mechanism underlying the observed changes in hTerT promoter activity in cancer cells is unclear, detailed investigations are needed. Here, cell cycle arrest at the S phase was demonstrated in Hela cells in response to cisplatin, in accordance with the results of other studies (22, 23) . it is known that telomerase synthesizes telomeres during the S phase, and that telomerase activity markedly increases during this phase of the cell cycle (24) . Furthermore, the hTerT promoter mediated gene therapy in a strictly cancer-and S-phase-specific manner (25) . Thus, we hypothesized that the up-regulation of hTerT promoter activity may also be the result of cell cycle arrest in the S phase induced by ciplatin.
gene-directed enzyme prodrug therapy (gdePT) is a form of tumor-targeted chemotherapy that has entered several clinical trials. The HrP/iaa system, a novel gdePT system, has shown great efficacy in killing tumor cells, exhibiting a strong bystander effect and significant synergism with radiation, as well as greater cytotoxicity to tumors than the well-known HSvtk/gcv system (26, 27) . HrP/iaa involves the delivery of a specific enzyme (HRP) that converts non-cytotoxic IAA into cytotoxic metabolites. When the HrP gene is targeted to (29, 30) . Tumor-specific expression of the HRP gene is crucial for minimizing the side effects of treatment. in this study, in order to improve hTerT promoter-mediated gdePT, phTerTp-HrP/iaa targeted gene therapy was combined with cisplatin exposure. The results revealed a synergistic inhibition of proliferation. although necrosis, dna fragmentation, chromatin condensation and apoptosis are involved in the cytotoxic effect of HrP/iaa gdePT (26, 31) , apoptosis is the most important mechanism of cytotoxicity (32) . combination strategy enhanced apoptosis in Hela cells and induced cell cycle arrest at the S phase. This is likely to contribute to the inhibition of proliferation in Hela cells. in this study, cisplatin-induced dna damage was used as a therapeutic tool and as an activator to enhance the activity of the hTerT promoter. The results provide further support for the ῾indirected-activator' strategy, by which DNA damage can be used to enhance the hTerT promoter in targeted gene therapy. This hypothesis may provide a novel explanation for the satisfactory results obtained by other researchers combining cisplatin with gene therapy using the hTerT promoter (9, (33) (34) (35) .
cisplatin is one of the most effective chemotherapeutic agents, and has been successfully used to treat tumors of the head, neck, lungs and genitourinary tract (36) . The hTerT promoter has been widely used in gene therapy for targeted cancer cells (3, 4) . combined with cisplatin, hTerT promoter-mediated cancer-targeted gene therapy approaches may achieve a more satisfactory curative effect. The results presented here demonstrate for the first time that cisplatin enhances the activity of the hTerT promoter in human uterine cervical cancer cells. our data support the hypothesis that the tumor-targeted hTerT promoter drives the transcription of transgenes in response to dna-damaging agents.
